A new anti-obesity drug on the horizon?;Nové antiobezitikum na obzoru?

Prakticky Lekar

Volumn 89, Issue 3, 2009, Pages 131-133

  Starka L ^a   Hainer, V ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Antiobesity drugs; Obesity; Side effects; Tesofensine; Weight reduction

Indexed keywords

EID: 65349122940     PISSN: 00326739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Anderson, J.W., Greenway, F.L., Fujioka K. et al. Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes. Res. 2002, 10, p. 633-641.
2. Astrup, A., Greenway, F.L., Ling, W. et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) 2007, 15, p. 1717-1731.
3. Astrup, A., Meier, D.H., Mikkelsen, B.O. et al. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008, 16, p. 1363-1369.
4. Astrup, A., Madsbad, S., Breum, L. et al. Effect of tesofensine on body weight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, p. 1906-1913.
5. Bayés, M., Rabasseda, X., Prous, J.R. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 2007, 29, p. 53-71.
6. Bray, G.A. Is new hope on the horizon for obesity? Lancet 2008, 372, p. 1859-1860.
7. Wren, A.M., Cooke, D., Bloom, S.R. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008, 68, p. 147-163.
8. Gadde, K.M., Parker, C.B., Maner, L.G. et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. 2001, 9, p. 544-551.
9. Hainer, V., Bělikovová, H. Dopaminergní systém a regulace tělesné hmotnosti. Čas. Lék. Čes., 1987, 126, s. 840-843.
10. Hainer, V., Kunešová, M., Pařízková ., J, Stun-kard, A. Zdravotní rizika a ekonomické náklady spojené s obezitou vyžadují komplexní program hmotnostní redukce. Čas. Lék. Čes., 1997, 136, s. 367-372.
11. Hainer, V., Kabrnová, K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann. NY Acad. Sci. 2006, 1083, p. 252-269.
12. Hauser, R.A., Salin, L., Juhel, N., Konyago, V.L. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov. Disord. 2007, 22, p. 359-365.
13. James, W.P., Astrup, A., Finer, N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356, p. 2119-2125.
14. Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Dis-cov. 2008, 7, p. 961-962.
15. Kok, P., Roelfsema, F., Frolich, M. et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am. J. Physiol. Endocrinol. Metab. 2006, 291, p. E1038-E1043.
16. Larsen, M.H., Rosenbrock, H., Sams-Dodd, F., Mikkelsen, J.D. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippo-campal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine reuptake inhibitor tesofensine. Eur. J. Pharmacol. 2007, 555, p. 115-121.
17. Lehr, T., Staab, A., Tillmann, C. et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br. J. Pharmacol. 2008, 153, p. 164-174.
18. Lehr, T., Staab, A., Tillmann, C. et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br. J. Clin. Pharmacol. 2007, 64, p. 36-48.
19. Pijl, H., Ohashi, S., Matsuda, M. et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23, p. 1154-1161.
20. Rascol, O., Poewe, W., Lees, A. et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch. Neurol., 2008, 65, p. 577-583.
21. Smith, S.R., Prosser, W.A., Donahue, D.J. et al. Lorcaserin (ADP356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2008 Dec 4 [Epub ahead of print].
22. Tomillero, A., Moral, M.A. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 2008, 30, p. 643-672.